Polydex Pharmaceuticals (POLXF) Stock Price, News & Analysis

Company Overview

Polydex Pharmaceuticals, trading on the OTCMKTS under the symbol POLXF, is a diversified pharmaceutical company engaged in the development, manufacturing and distribution of prescription and over-the-counter medications. With operations spanning North America, Europe and select Asian markets, the company offers a portfolio of products in therapeutic areas such as cardiovascular health, anti-infectives, dermatology and ophthalmology. Polydex’s product range includes both branded and generic formulations, enabling it to serve hospital, retail and specialty pharmacy channels.

Founded in the early 1980s, Polydex Pharmaceuticals established its headquarters in Miami, Florida, following an initial period of growth in Canada. Over the decades the company has invested in cGMP-compliant manufacturing facilities and strategic partnerships with contract manufacturers to ensure a reliable supply chain. This global infrastructure supports Polydex’s ability to scale production quickly and respond to evolving regulatory requirements in multiple jurisdictions.

In addition to its core branded and generic offerings, Polydex maintains a dedicated contract development and manufacturing organization (CDMO) segment that provides fill-finish, packaging and regulatory support services to emerging biotechnology firms. Its in-house research and development group focuses on novel drug-delivery technologies—such as extended-release oral dosage forms and transdermal patches—to enhance therapeutic efficacy and patient compliance.

Leadership at Polydex Pharmaceuticals is headed by Chief Executive Officer John Thomson, a veteran of the pharmaceutical industry with more than 25 years of experience in product development and global commercialization. Chief Financial Officer Linda Cheng brings expertise in corporate finance and merger-and-acquisition strategy, while the company’s board features professionals with backgrounds in regulatory affairs, clinical research and commercial operations. Under this leadership, Polydex continues to pursue pipeline expansion and geographic diversification to drive long-term growth.

Key Stats

• Today's Range: $1.99 to $1.99
• 50-Day Range: $1.99 to $1.99
• 52-Week Range: $0.55 to $2.01
• Volume: 2,000 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

POLXF Stock Analysis - Frequently Asked Questions

How have POLXF shares performed this year?

Polydex Pharmaceuticals' stock was trading at $1.9860 on January 1st, 2025. Since then, POLXF shares have increased by 0.0% and is now trading at $1.9860.

How do I buy shares of Polydex Pharmaceuticals?

Shares of POLXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/20/2025
• Fiscal Year End: 1/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:POLXF
• CIK: 317158
• Web: www.polydex.com
• Phone: (416) 755-2231
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $4.41 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A